AIDS and Behavior

, Volume 17, Issue 2, pp 760–772 | Cite as

Recruitment of Urban US Women at Risk for HIV Infection and Willingness to Participate in Future HIV Vaccine Trials

  • Barbara Metch
  • Ian Frank
  • Richard Novak
  • Edith Swann
  • David Metzger
  • Cecilia Morgan
  • Debbie Lucy
  • Debora Dunbar
  • Parrie Graham
  • Tamra Madenwald
  • Gina Escamilia
  • Beryl Koblin
Original Paper
First Online:

Abstract

Enrollment of US women with sufficient risk of HIV infection into HIV vaccine efficacy trials has proved challenging. A cohort of 799 HIV-negative women, aged 18–45, recruited from three US cities was enrolled to assess recruitment strategies based on geographic risk pockets, social and sexual networks and occurrence of sexual concurrency and to assess HIV seroincidence during follow-up (to be reported later). Among enrolled women, 90 % lived or engaged in risk behaviors within a local risk pocket, 64 % had a male partner who had concurrent partners and 50 % had a male partner who had been recently incarcerated. Nearly half (46 %) were recruited through peer referral. At enrollment, 86 % of women said they were willing to participate in a vaccine efficacy trial. Results indicate that participant and partner risk behaviors combined with a peer referral recruitment strategy may best identify an at-risk cohort willing to participate in future trials.

Keywords

HIV vaccine trial preparedness United States women Peer referral Respondent driven sampling Sexual concurrency Willingness to participate 

Resumen

Inscripción de las mujeres estadounidenses con suficiente riesgo de infección por el VIH en los ensayos de eficacia de vacunas contra el VIH ha resultado difícil. Una cohorte de 799 mujeres VIH negativas, 18–45 años de edad, reclutadas en tres ciudades de Estados Unidos estaba inscrito para evaluar las estrategias de reclutamiento basado en los bolsillos de riesgo geográfico, las redes sociales y sexuales y la aparición de la concurrencia sexual y evaluar seroincidencia VIH durante el seguimiento (que se informara más adelante). Entre las mujeres matriculadas, el 90 % vivían o tenían conductas de riesgo dentro de una bolsa local de riesgo, el 64 % tenían una pareja masculina que tenían parejas concurrentes y el 50 % tenía un compañero que recientemente había sido encarcelado. Casi la mitad (46 %) fueron reclutadas a través de referencias de pares. Al inicio del estudio, el 86 % de las mujeres dijeron que estaban dispuestos a participar en un ensayo de eficacia de la vacuna. Los resultados indican que las conductas de los participantes y socio de riesgo en combinación con una estrategia de reclutamiento remisión semejante mejor puede identificar una cohorte de riesgo dispuestos a participar en los ensayos futuros.

This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The authors would like to thank the study participants, community advisory board members, and the study site staff, in particular the site recruiting staff, for their commitment to this study. This research was funded by the Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health, Grants 1UM1AI068614, 1UM1A1069470, 1UM1A1069554, 1UM1A1069534, and 1UM1AI068635.

References

  1. 1.
    Djomand G, Metch B, Zorrilla CD, et al. The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2008;48(1):82–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Koblin BA, Taylor PE, Avrett S, Stevens CE. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: project achieve. AIDS Community health initiative enroute to the vaccine effort. AIDS. 1996;10(13):1555–61.PubMedCrossRefGoogle Scholar
  3. 3.
    Buchbinder SP, Douglas JM Jr, McKirnan DJ, Judson FN, Katz MH, MacQueen KM. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis. 1996;174(5):954–61.PubMedCrossRefGoogle Scholar
  4. 4.
    UNAIDS. World AIDS day report. 2011.Google Scholar
  5. 5.
    Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001;344(10):720–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347(21):1652–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002;35(3):313–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS ONE. 2011;6(8):e17502.PubMedCrossRefGoogle Scholar
  9. 9.
    Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET vaccine preparedness study. Am J Epidemiol. 2001;153(7):619–27.PubMedCrossRefGoogle Scholar
  10. 10.
    Seage GR III, Holte S, Gross M, et al. Case-crossover study of partner and situational factors for unprotected sex. J Acquir Immune Defic Syndr. 2002;31(4):432–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654–65.PubMedCrossRefGoogle Scholar
  12. 12.
    Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Donnell D, Hughes JP, Fleming TR. Challenges in the design of HIV prevention trials in the United States. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S136–40.PubMedCrossRefGoogle Scholar
  14. 14.
    (14) Centers for Disease Control and Prevention. HIV among women fact sheet. http://www.cdc.gov/hiv/topics/women/index.htm. 2011. 6-15-0012.
  15. 15.
    Laumann EO, Youm Y. Racial/ethnic group differences in the prevalence of sexually transmitted diseases in the United States: a network explanation. Sex Transm Dis. 1999;26(5):250–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Aral SO. Sexual network patterns as determinants of STD rates: paradigm shift in the behavioral epidemiology of STDs made visible. Sex Transm Dis. 1999;26(5):262–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Rothenberg R, Muth SQ, Malone S, Potterat JJ, Woodhouse DE. Social and geographic distance in HIV risk. Sex Transm Dis. 2005;32(8):506–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Friedman SR, Neaigus A, Jose B, et al. Sociometric risk networks and risk for HIV infection. Am J Public Health. 1997;87(8):1289–96.PubMedCrossRefGoogle Scholar
  19. 19.
    Rothenberg RB, Long DM, Sterk CE, et al. The Atlanta urban networks study: a blueprint for endemic transmission. AIDS. 2000;14(14):2191–200.PubMedCrossRefGoogle Scholar
  20. 20.
    Becker KM, Glass GE, Brathwaite W, Zenilman JM. Geographic epidemiology of gonorrhea in Baltimore, Maryland, using a geographic information system. Am J Epidemiol. 1998;147(7):709–16.PubMedCrossRefGoogle Scholar
  21. 21.
    Bernstein KT, Curriero FC, Jennings JM, Olthoff G, Erbelding EJ, Zenilman J. Defining core gonorrhea transmission utilizing spatial data. Am J Epidemiol. 2004;160(1):51–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Zenilman JM, Ellish N, Fresia A, Glass G. The geography of sexual partnerships in Baltimore: applications of core theory dynamics using a geographic information system. Sex Transm Dis. 1999;26(2):75–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Potterat JJ, Rothenberg RB, Woodhouse DE, Muth JB, Pratts CI, Fogle JS. Gonorrhea as a social disease. Sex Transm Dis. 1985;12(1):25–32.PubMedCrossRefGoogle Scholar
  24. 24.
    De P, Singh AE, Wong T, Yacoub W, Jolly AM. Sexual network analysis of a gonorrhoea outbreak. Sex Transm Infect. 2004;80(4):280–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Binson D, Woods WJ, Pollack L, Paul J, Stall R, Catania JA. Differential HIV risk in bathhouses and public cruising areas. Am J Public Health. 2001;91(9):1482–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Watts CH, May RM. The influence of concurrent partnerships on the dynamics of HIV/AIDS. Math Biosci. 1992;108(1):89–104.PubMedCrossRefGoogle Scholar
  27. 27.
    Morris M, Zavisca J, Dean L. Social and sexual networks: their role in the spread of HIV/AIDS among young gay men. AIDS Educ Prev. 1995;7(5 Suppl):24–35.PubMedGoogle Scholar
  28. 28.
    Youm Y, Laumann EO. Social network effects on the transmission of sexually transmitted diseases. Sex Transm Dis. 2002;29(11):689–97.PubMedCrossRefGoogle Scholar
  29. 29.
    Adimora AA, Schoenbach VJ, Martinson FE, Donaldson KH, Stancil TR, Fullilove RE. Concurrent partnerships among rural African Americans with recently reported heterosexually transmitted HIV infection. J Acquir Immune Defic Syndr. 2003;34(4):423–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Adimora AA, Schoenbach VJ, Taylor EM, Khan MR, Schwartz RJ. Concurrent partnerships, nonmonogamous partners, and substance use among women in the United States. Am J Public Health. 2011;101(1):128–36.PubMedCrossRefGoogle Scholar
  31. 31.
    Tanser F, Barnighausen T, Hund L, Garnett GP, McGrath N, Newell ML. Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study. Lancet. 2011;378(9787):247–55.PubMedCrossRefGoogle Scholar
  32. 32.
    Adimora AA, Schoenbach VJ, Floris-Moore MA. Ending the epidemic of heterosexual HIV transmission among African Americans. Am J Prev Med. 2009;37(5):468–71.PubMedCrossRefGoogle Scholar
  33. 33.
    Adimora AA, Schoenbach VJ, Doherty IA. Concurrent sexual partnerships among men in the United States. Am J Public Health. 2007;97(12):2230–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Grinstead OA, Faigeles B, Comfort M, et al. HIV, STD, and hepatitis risk to primary female partners of men being released from prison. Women Health. 2005;41(2):63–80.PubMedCrossRefGoogle Scholar
  35. 35.
    CDC. Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence—24 cities, United States, 2006–2007. MMWR Morb Mortal Wkly Rep 2011; 60(31):1045–1049.Google Scholar
  36. 36.
    Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS ONE. 2009;4(11):e7558.PubMedCrossRefGoogle Scholar
  37. 37.
    Thomas JC, Sampson LA. High rates of incarceration as a social force associated with community rates of sexually transmitted infection. J Infect Dis. 2005;191(Suppl 1):S55–60.PubMedCrossRefGoogle Scholar
  38. 38.
    Gorbach PM, Drumright LN, Holmes KK. Discord, discordance, and concurrency: comparing individual and partnership-level analyses of new partnerships of young adults at risk of sexually transmitted infections. Sex Transm Dis. 2005;32(1):7–12.PubMedCrossRefGoogle Scholar
  39. 39.
    Adimora AA, Schoenbach VJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis. 2005;191(Suppl 1):S115–22.PubMedCrossRefGoogle Scholar
  40. 40.
    Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35(3):305–12.PubMedCrossRefGoogle Scholar
  41. 41.
    Adams LM, Kendall S, Smith A, Quigley E, Stuewig JB, Tangney JP. HIV risk behaviors of male and female jail inmates prior to incarceration and one year post-release. AIDS Behav 2011 (in press).Google Scholar
  42. 42.
    Frew PM, Archibald M, Hixson B, del Rio C. Socioecological influences on community involvement in HIV vaccine research. Vaccine. 2011;29(36):6136–43.PubMedCrossRefGoogle Scholar
  43. 43.
    Newman PA, Duan N, Roberts KJ, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr. 2006;41(2):210–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Mills E, Cooper C, Guyatt G, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004;18(17):2235–42.PubMedCrossRefGoogle Scholar
  45. 45.
    Strauss RP, Sengupta S, Kegeles S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J Acquir Immune Defic Syndr. 2001;26(1):63–71.PubMedGoogle Scholar
  46. 46.
    Rudy ET, Newman PA, Duan N, Kelly EM, Roberts KJ, Seiden DS. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev. 2005;17(3):253–67.PubMedCrossRefGoogle Scholar
  47. 47.
    Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12(7):785–93.PubMedCrossRefGoogle Scholar
  48. 48.
    Voytek CD, Jones KT, Metzger DS. Selectively willing and conditionally able: HIV vaccine trial participation among women at “high risk” of HIV infection. Vaccine. 2011;29(36):6130–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Buchbinder SP, Metch B, Holte Se, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36:604–12.PubMedCrossRefGoogle Scholar
  50. 50.
    Dhalla S, Poole G. Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. Vaccine. 2011;29:5850–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:359–64.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Barbara Metch
    • 1
  • Ian Frank
    • 2
    • 3
  • Richard Novak
    • 4
  • Edith Swann
    • 5
  • David Metzger
    • 3
  • Cecilia Morgan
    • 1
  • Debbie Lucy
    • 6
  • Debora Dunbar
    • 3
  • Parrie Graham
    • 4
  • Tamra Madenwald
    • 1
  • Gina Escamilia
    • 1
  • Beryl Koblin
    • 6
  1. 1.Vaccine and Infectious Disease DivisionFred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Infectious Diseases DivisionUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.HIV Prevention DivisionUniversity of PennsylvaniaPhiladelphiaUSA
  4. 4.Section of Infectious DiseasesUniversity of Illinois at ChicagoChicagoUSA
  5. 5.Division of AIDSNational Institute of Allergy and Infectious Diseases NIHBethesdaUSA
  6. 6.Laboratory of Infectious Disease Prevention, New York Blood CenterNew YorkUSA

Personalised recommendations